Tax

Excess Tax Benefits from Share-Based Compensation

Intuitive Surgical Excess Tax Benefits from Share-Based Compensation increased by 202.9% to $73.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 49.6%, from $145.40M to $73.30M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementIncome Statement
SectionTax
CategoryProfitability
SignalHigher is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026Apr 22, 2026

How to read this metric

An increase indicates higher employee stock performance or increased exercise activity, leading to lower cash taxes paid.

Detailed definition

This represents the tax savings realized when the actual tax deduction from employee stock option exercises or restricte...

Peer comparison

Commonly reported by large-cap companies with significant equity-based compensation plans.

Metric ID: tmo_excess_tax_benefits_share_based_compensation

Historical Data

15 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$43.60M$41.90M$53.00M$9.30M$18.10M$22.50M$41.70M$22.00M$111.10M$35.70M$42.20M$145.40M$32.90M$24.20M$73.30M
QoQ Change-3.9%+26.5%-82.5%+94.6%+24.3%+85.3%-47.2%+405.0%-67.9%+18.2%+244.5%-77.4%-26.4%+202.9%
YoY Change-78.7%-56.8%-57.5%+348.4%+21.5%+393.8%-14.4%+91.8%+30.9%-7.8%-42.7%-49.6%
Range$9.30M$145.40M
CAGR+16.0%
Avg YoY Growth+48.2%
Median YoY Growth-11.1%

Frequently Asked Questions

What is Intuitive Surgical's excess tax benefits from share-based compensation?
Intuitive Surgical (ISRG) reported excess tax benefits from share-based compensation of $73.30M in Q1 2026.
How has Intuitive Surgical's excess tax benefits from share-based compensation changed year-over-year?
Intuitive Surgical's excess tax benefits from share-based compensation decreased by 49.6% year-over-year, from $145.40M to $73.30M.
What does excess tax benefits from share-based compensation mean?
The tax savings generated when employees exercise stock options at prices higher than the grant value.